Loading
Respiratory Viral Infections Research · Journal article
Journal of Clinical Medicine · July 8, 2026
Well-designed and adequately powered for the question it asks.
This narrative review synthesizes evidence that influenza vaccination reduces major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality in adults with established cardiovascular disease, particularly those with prior myocardial infarction or heart failure. Recent pragmatic trials of high-dose vaccine in older adults support benefits for hospitalization outcomes. The source positions vaccination as an evidence-supported component of secondary cardiovascular prevention alongside guideline-directed therapy, though specific effect estimates and confidence intervals are not provided.
Journal article. Adults with established cardiovascular disease, particularly older adults and patients with recent acute coronary syndrome or heart failure.
Randomized trials and meta-analyses support reductions in major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality in higher-risk secondary-prevention populations Particularly persuasive evidence exists after myocardial infarction DANFLU-2, GALFLU, and FLUNITY-HD pooled analysis provide incremental evidence in adults aged 65 years or older for hospitalization for influenza or pneumonia, cardiorespiratory hospitalization, and heart failure hospitalization
Randomized trials and meta-analyses support reductions in major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality in higher-risk secondary-prevention populations
Clinicians should offer influenza vaccination to all adults with established cardiovascular disease as a low-risk, evidence-supported component of secondary cardiovascular prevention. Implementation across multiple care settings (hospitalization, cardiology, cardiac rehabilitation, primary care, pharmacies, long-term care) is identified as the current priority.
Multiple randomized trials and meta-analyses support reductions in major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality in secondary-prevention populations, with particularly persuasive evidence after myocardial infarction, though the source does not report specific effect sizes or confidence intervals.
Clinicians should offer influenza vaccination to all adults with established cardiovascular disease as a low-risk, evidence-supported component of secondary cardiovascular prevention. Implementation across multiple care settings (hospitalization, cardiology, cardiac rehabilitation, primary care, pharmacies, long-term care) is identified as the current priority.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Seasonal influenza is not only a respiratory infection but also a clinically relevant trigger of acute cardiovascular events. In adults with established cardiovascular disease, particularly older adults and patients with recent acute coronary syndrome or heart failure, influenza vaccination should be considered a low-risk, evidence-supported component of cardiovascular prevention rather than solely protection against respiratory disease. The evidence addresses three related but distinct questions: influenza infection as a cardiovascular trigger; influenza vaccination versus placebo or no vaccination; and enhanced or high-dose vaccination versus standard-dose vaccination. Randomized trials and meta-analyses support reductions in major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality in higher-risk secondary-prevention populations, with particularly persuasive evidence after myocardial infarction. Recent pragmatic active-comparator trials of high-dose inactivated influenza vaccine, including DANFLU-2 and GALFLU, and the individual-level pooled FLUNITY-HD analysis provide incremental evidence in adults aged 65 years or older, strongest for hospitalization for influenza or pneumonia, cardiorespiratory hospitalization, and heart failure hospitalization. The current priority is implementation: screening, offering, documenting, and communicating vaccination across hospitalization, outpatient cardiology, cardiac rehabilitation, heart failure pathways, primary care, pharmacies, and long-term care. Influenza vaccination should complement, not replace, established guideline-directed cardiovascular therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.